KEYMED BIOSCIENCES -0001 (64Z) - Total Assets
Based on the latest financial reports, KEYMED BIOSCIENCES -0001 (64Z) holds total assets worth €4.22 Billion EUR (≈ $4.93 Billion USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore KEYMED BIOSCIENCES -0001 debt service capacity to assess how comfortably operating cash covers total debt obligations.
KEYMED BIOSCIENCES -0001 - Total Assets Trend (2021–2025)
This chart illustrates how KEYMED BIOSCIENCES -0001's total assets have evolved over time, based on quarterly financial data. See net assets of KEYMED BIOSCIENCES -0001 for net asset value and shareholders' equity analysis.
KEYMED BIOSCIENCES -0001 - Asset Composition Analysis
Current Asset Composition (December 2025)
KEYMED BIOSCIENCES -0001's total assets of €4.22 Billion consist of 57.5% current assets and 42.6% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 11.9% |
| Accounts Receivable | €100.85 Million | 2.4% |
| Inventory | €195.98 Million | 4.7% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €10.57 Million | 0.3% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2021–2025)
This chart illustrates how KEYMED BIOSCIENCES -0001's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 64Z stock market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: KEYMED BIOSCIENCES -0001's current assets represent 57.5% of total assets in 2025, a decrease from 91.0% in 2021.
- Cash Position: Cash and equivalents constituted 11.9% of total assets in 2025, down from 38.7% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2021.
- Asset Diversification: The largest asset category is inventory at 4.7% of total assets.
KEYMED BIOSCIENCES -0001 Competitors by Total Assets
Key competitors of KEYMED BIOSCIENCES -0001 based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
ALTEOGEN Inc
KQ:196170
|
Korea | ₩729.47 Billion |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE
|
USA | $1.29 Billion |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX
|
USA | $440.10 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Galapagos N.V.
AS:GLPG
|
Netherlands | €3.37 Billion |
|
Blue Jet Healthcare Limited
NSE:BLUEJET
|
India | Rs16.41 Billion |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
KEYMED BIOSCIENCES -0001 - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.90 | 3.30 | 4.98 |
| Quick Ratio | 2.66 | 3.15 | 4.83 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €1.59 Billion | €1.72 Billion | €2.23 Billion |
KEYMED BIOSCIENCES -0001 - Advanced Valuation Insights
This section examines the relationship between KEYMED BIOSCIENCES -0001's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.57 |
| Latest Market Cap to Assets Ratio | 0.54 |
| Asset Growth Rate (YoY) | 12.0% |
| Total Assets | €4.22 Billion |
| Market Capitalization | $2.28 Billion USD |
Valuation Analysis
Below Book Valuation: The market values KEYMED BIOSCIENCES -0001's assets below their book value (0.54x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: KEYMED BIOSCIENCES -0001's assets grew by 12.0% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for KEYMED BIOSCIENCES -0001 (2021–2025)
The table below shows the annual total assets of KEYMED BIOSCIENCES -0001 from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €4.22 Billion ≈ $4.93 Billion |
+11.97% |
| 2024-12-31 | €3.77 Billion ≈ $4.40 Billion |
-3.00% |
| 2023-12-31 | €3.88 Billion ≈ $4.54 Billion |
-1.26% |
| 2022-12-31 | €3.93 Billion ≈ $4.60 Billion |
-0.05% |
| 2021-12-31 | €3.93 Billion ≈ $4.60 Billion |
-- |
About KEYMED BIOSCIENCES -0001
Keymed Biosciences Inc., a biotechnology company, engages in the discovery and development of biological therapies in the autoimmune and oncology therapeutic areas in Mainland China and internationally. Its lead product candidate is CM310 for the treatment of moderate to severe atopic dermatitis (AD), chronic rhinosinusitis with nasal polyposis (CRSwNP), seasonal allergic rhinitis, prurigo nodula… Read more